Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi Taps Foundation Medicine for Biomarker, Companion Dx Discovery

NEW YORK (GenomeWeb News) – Foundation Medicine said today that it will use its genome sequencing and analysis services to identify genetic biomarkers and potential companion diagnostics for oncology drug candidates for Sanofi.

Foundation Medicine uses next-generation sequencing to analyze clinical specimens for molecular alterations in around 200 cancer-related genes. Its cancer genomic test is designed to provide clinical-grade analysis of tumor tissues, and test results are reported through a secure website that links pertinent genomic data to a knowledge base of relevant, publicly available data.

"Targeted cancer therapeutics routinely demonstrate improved clinical safety and efficacy when matched with the patients most likely to benefit, and we believe this alliance with Sanofi will help catalyze the development of their targeted candidates," Foundation Medicine President and CEO Michael Pellini said in a statement.

Financial terms of the agreement were not released.

The agreement with Sanofi marks the company's fifth collaboration with a pharmaceutical firm. It has signed similar deals with Johnson & Johnson Pharmaceutical Research and Development, Novartis, Celgene, and an undisclosed firm.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.